Biotech News

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Tenaya Therapeutics (TNYA)Tenaya TherapeuticsCompany update

Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially

Related news

Tenaya Therapeutics

Genetically Informed Cardiac Therapies Tenaya Therapeutics develops gene therapies and small molecules that address underlying drivers of inherited and prevalent heart disease. TN-201 TN-201 is an AAV gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 mutations. The Phase 1b/2 MyPEAK-1 study is evaluating two dose cohorts in...

Recent company news

Stock data

Close
0.70 USD
Market cap
171.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States